U
TEVA icon

UBS’s Teva Pharmaceuticals TEVA Stock Holding History

UBS’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$74.7M Buy
1,389,100
+1,203,300
+648% +$63.7M 0.06% 347
2014
Q2 		$9.74M Sell
185,800
-204,000
-52% -$10.4M 0.01% 1399
2014
Q1 		$20.6M Buy
389,800
+261,000
+203% +$12.1M 0.02% 778
2013
Q4 		$5.16M Buy
128,800
+94,100
+271% +$3.71M ﹤0.01% 1837
2013
Q3 		$1.31M Sell
34,700
-145,800
-81% -$5.69M ﹤0.01% 3030
2013
Q2 		$7.08M Buy
+180,500
New +$7.03M 0.01% 1307

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS's TEVA Position: Q3 2014 in Review

UBS increased its Teva Pharmaceuticals (TEVA) stake by 27% in Q3 2014, buying an estimated $32.9M and bringing the position to 2,925,533 shares worth $157M. The position accounts for 0.12% of the portfolio, ranked #192.

UBS first reported a position in TEVA in Q2 2013 and has held it in 6 quarters since. The position peaked at $265M in Q4 2013. 772 funds tracked by Wall St. Rank hold TEVA as of Q3 2014.

  • UBS held 2,925,533 shares of Teva Pharmaceuticals worth $157M as of Q3 2014.
  • UBS bought 621,771 Teva Pharmaceuticals shares in Q3 2014, an estimated $32.9M.
  • Teva Pharmaceuticals made up 0.12% of UBS's portfolio in Q3 2014, its #192 holding.
  • UBS first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Teva Pharmaceuticals position peaked at $265M in Q4 2013.
  • 772 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.